Cancer Chemotherapy (Drugs) Flashcards

1
Q

describe the toxicity of chemotherapy druges

A
  • all chemotherapeutic agents are toic
  • goal: selective toxicity
  • toxicity to pathogen vs host is relative, not absolute
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the different classes of chemotherapy drugs

A
  1. alkylating agents
  2. antimetabolites
  3. antitumor antibiotics
  4. microtubule poisons
  5. topoisomerase inhibitors
  6. target therapies: signal pathways, not proliferation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is the mechanism of action, types of resistance, and adverse effects for alkylating agents? how do you know if these drugs are working? what is the dose-limiting toxic effect?

A

mechanism: covalently bind to/modify biological molecules - DNA; must be reactive and are CCNS (replicating cells are more sensitive); on DNA, are bifunctional in that they can make pyrimidine dimers or cross link DNA
* covalent modification is key*
resistance: drug cannot get into cell (impermeable), pump drug out, increased DNA repair, no apoptosis (no p53), and may have alternate targets for drug (Glutathione)

adverse effects: secondary malignancy (normal cells will get mutations), other rapidly growing cells are targeted (bone marrow, GI, spermatogenesis)

know if they are working by looking at CBC - should see decreased leukocytes, platelets and hematocrit

dose-limiting toxic effect: decreased leukocytes and platelets; given in cycles -> will give as much as the patient can tolerate and then wait for the patient to recover

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the mechanism of action of antimetabolites? what are the three main types (not drugs, but types)

A

analog of a normal component in the target cell and it competes with this normal component by entering into the normal metabolic pathway and either blocking or altering the pathway

types:
folate analogs
purine analogs
pyrimidine analogs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are antitumor antibiotics? how do they work and how are they given to patients? anything special?

A

they block access to/function of DNA/RNA but not through alkylation

given intravenously and there are unique toxicities associated with these compounds

most are produced by microbes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

how do microtubule poisons work?

A

by causing metaphase arrest either via stabilization of microtubules or inhibition of microtubules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what do the current target pathway drugs target? give examples of these targets

A

target signaling pathways driving proliferation, not specific characteristics of proliferation

  • inhibit agonist synthesis or release
  • agonist scavengers
  • receptor antagonists
  • anti-receptor MAb
  • tyrosine kinase inhibitors

also hormonal therapy - acivity requires functional hormone receptor

  • androgens: prostate
  • estrogens: breast, uterus, cervix
  • corticosteroids: leukocytes, lymphocytes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

mechlorethamine

A
  • alkylating agent
  • IV only (in arterial supply to tumor)
  • short half-life
  • adverse effects: nausea, vomiting, decreased CBC (min levels 10-12 days after tx)
  • primary use: hodgkin’s disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

cyclophosphamide

A
  • alkylating agent
  • IV or oral
  • is a pro-drug; metabolized in liver to active form
  • adverse effects: nausea, vomiting, bone marrow depression, alopecia (hair loss), sterile hemorrhagic cystitis (no infection, blood in urine - caused by acrolein from metabolism)
  • special: protect from sterile hemorrhagic cystitis by forced hydration or Mesna (thiol which reacts with acrolein)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

cis-platin

A
  • alkylating agent…platinum complex
  • bifunctional: cross-links DNA; blocks DNA synthesis
  • IV (cleared in urine)
  • relatively non-toxic to bone marrow
  • adverse effects: severe nausea and vomiting
  • special: renal toxicity is dose-limiting…ensure adequate hydration; also, use HT3 antagonists (ondansetron) to help with nausea…block serotonin receptor (but only works on 70% of patients)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

methotrexate

A
  • antimetabolite
  • competes with folic acid by binding to and inhibiting diydrofolate reductase (DHFR) (this enzyme converts the inactive form of folic acid to the active form)
  • this blocks DNA synthesis because U cannot be converted to T (ie blocks production of bases for DNA synthesis)
  • greater accumulation in tumor cells
  • orally, IV, intrathecally (spinal cord because cannot pass BBB)
  • excreted in urine
  • adverse effects: bone marrow, GI
  • resistance: decreased drug accumulation, amplified DHFR, altered DHFR, pumped out by MDR1 (ATP driven)
  • may give a high dose followed by “rescue” with citrovorin or leucovorin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

purine analogues (drug and mechanism)

A
  • drugs: 6-Mercaptopurine (inhibits AMP and GMP synthesis) and 6-Thioguanine (incorporated into RNA and DNA)
  • inhibit synthesis of essential precurosrs of DNA (affects guanine)
  • oral
  • inactivated by thiopurine methyltransferase (TPMT)…if patient does not have enough of this, fatal myelosuppression will occur
  • requires purine salvage pathway: hprt
  • competes with normal bases to block/alter nucleic acid synthesis
  • adverse effects: well tolerated, bone marrow affected only at high doses
  • resistance: decrease in hprt activity or increase in alkaline phosphatase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

pyrimidine analogues (drug and mechanism)

A
  • drugs: 5-Flouorouracil (5-FU…inhibits thymidylate synthase in its FdUMP form) and Gemcitabine (cytosine analogue; inhibits polymerase and chain terminator)
  • inhibits synthesis of essential precursors of DNA
  • adverse effects: bone marrow, GI (far more toxic than purines)
  • in order for 5-FU to work, need to have folinic acid in the active site of thymidylate synthase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

anthracyclines

A
  • antitumor antibiotic
  • drugs: doxorubicin and daunorubicin
  • intercalate into DNA, which blocks topoisomerase II, inhibits DNA/RNA synthesis and causes strand breaks
  • generates free radicals -> causes cardiotoxicity because free radicals target cardiomyocyte mitochondria…function of cumulative dose and can minimize this effect by: Dexrazoxane
  • IV
  • metabolized in liver
  • adverse effect: bone marrow suppression, GI distress, severe alopecia (hair loss)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Bleomycin

A
  • antitumor antibiotic
  • CCS: active in G2
  • binds to DNA, generates free radicals, causes strand breaks
  • adverse effects: pulmonary fibrosis, hypersensitivity, cutaneous reactions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

vincas

A
  • microtubule poisons: inhibits/reverses tubulin polymerization, disrupts mitotic spindles (mmicrotubules)
  • causes metaphase arrest
  • IV
  • biliary excretion

types. ..
1. vinblastine: nausea and vomiting, alopecia, bone marrow depression
2. vincristine: less toxic to bone marrow, no nausea and vomiting; but causes peripheral neuropathy so only use for a short time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

taxanes

A
  • microtubule poisons: stabilizes the mt and blocks progression through mitosis (mt cannot depolymerize)
  • IV
  • acute hypersensitivity, nausea, delayed bone marrow suppression, some neuropathy
  • drugs: paclitaxel and docetaxel
18
Q

irinotecan

A
  • topoisomerase inhibitor: camptothecins
  • pro drug; converted to active SN-38 by esterase
  • SN-38 inhibits topo I and causes nausea, vomiting, diarrhea (dose-limiting effect), bone marrow suppression
  • UGT1A1 is an enzyme that contributes to hematological toxicity of drug…inactivates SN-38
19
Q

what do polymorphisms in UGT1A1 cause?

A
  • increased sensitivity to irinotecan
  • Crigler-Najjar syndrome
  • Gilbert’s disease
  • Hyperbilirubinemia
20
Q

aromatase inhibitor

A
  • targeted hormone therapy
  • blocks conversion of androgens to estrogens; use in post-menopausal women
  • drugs: anastrazole, letrozole
  • treatment for primary ER+ and metastatic breast cancer
  • adverse effects: nausea, headache, fatigue, hot flushes
21
Q

SERM

A
  • selective estrogen receptor antagonists: competing ligands for ER
  • tamoxifen…ER antagonist in breast but ER agonist in endometrium; orally; activated by CYP2D6 to a more potent form
  • treatmetn for ER+ primary and metastatic breast cancer
  • adverse effects: nausea, hot flushes, vaginal bleeding
22
Q

androgen receptor antagonists

A
  • diminish androgen effects by binding to AR
  • drug: flutamide
  • oral
  • used with radiation for prostate cancer
  • adverse effects: nausea, hot flushes, transient hepatic effects
23
Q

trastuzumab

A
  • biological antineoplastic agents
  • monoclonal antibody against HER2/neu oncogene product
  • does not cross BBB
  • EGFR receptor amplified in ~25% of breast cancers, poor prognosis
  • IV
  • adverse reactions: hypersensitivity, cardiomyopathy, infusion reactions
24
Q

imatinib

A
  • tyrosine kinase inhibitors
  • inhibits BCR-ABL and other tyr kinases -> specific for chronic myelogenous leukemia (CML)
  • also blocks kit kinase in GI stromal tumors (GIST)
  • myelosuppressive
  • edema and fluid retention, hepatotoxicity
25
Q

dasatinib

A
  • overcomes imatinib resistance

- is a second generation BCR-ABL inhibitor -> tyrosine kinase inhibitor

26
Q

gefitinib

A
  • inhibits EGFR tyrosine kinase
  • oral
  • works best with non-small cell lung cancer, asian women who do not smoke
  • all about the genetics of the tumor
  • may cause fever, dyspnea
27
Q

what is the importance of STI (selective tyrosine inhibitors) and when does this treatment stop?

A
  • transforms cancer from a “curable” disease to a “manageable” disease
  • focuses on the genetics of the tumor
  • treatment continues until the tumor gains resistance, the patient dies, or the patient chooses to discontinue the drug
28
Q

pertuzumab

A

HER2/neu + breast cancer tumor; inhibition of ligand-dependent signaling (so the ligand is there and pertuzumab will inhibit signaling); inhibited formation of ligand-dependent heterodimers

29
Q

lapatinib

A

inhibition of ligand-dependent and ligand-independent signaling for HER2/neu + breast cancer tumor

30
Q

herceptin

A

used in HER2/neu + treatment; attaches to HER2 and blocks dimerization

31
Q

tykerb

A

tyrosine kinase inhibitor

32
Q

what are the alkylating agents?

A

cyclophosphamide, mechlorethamine, cis-platin

33
Q

antimetabolites

A

5-FU, gemcitabine, 6-mercaptopurine, methotrexate, thioguanine

34
Q

antitumor antibodies

A

bleomycin, daunorubicin, doxorubicin

35
Q

mt poisons

A

docetaxel, paclitaxel, vinblastine, vincristine

36
Q

topo inhibitors

A

irinotecan

37
Q

targeted therapies - hormonal agents

A

anastraxole, letrozole, flutamide, tamoxifen

38
Q

targeted therapies - biologicals

A

trastuzamab, gefitinib, imatinib

39
Q

targeted therapies - tyrosine kinase inhibitors

A

dasatinib

40
Q

ancillary drugs

A
  1. dexrazoxane - used with anthracyclines to help stop free radical damage to mitochondria in cardiomyocytes
  2. erythropoietin - used to help stimulate RBC production/help the bone marrow
  3. GM-CSF - used to help stimulate granulocyte and macrophage production
  4. Mesna - used to help treat uterine toxicity when given cyclophosphamide
  5. ondansetron - HT3 used to help with nausea, especially with cis-platin
41
Q

tolvaptin

A

blocks the vasopressin receptor which will decrease the [cAMP] in the cell; patients are EXTREMELY thirsty